-
Exploring the impact of BRCA1 and BRCA2 mutation type and location on olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer patients : a single center reportŠkof, Erik ...Objective: In patients with platinum-sensitive relapsed ovarian cancer (PSROC) harboring pathogenic/likely pathogenic variants (PV) in BRCA1 and BRCA2 genes, olaparib maintenance monotherapy (OMT) is ... a viable option. Our study aimed to evaluate the impact of different BRCA1/2 PV in survival outcomes and safety of OMT in BRCA1/2-mutated PSROC patients, focusing on the type and location of PV. Methods: We assessed the outcomes of 100 BRCA1/2-mutated PSROC patients treated at our institute, analyzing progression-free survival (PFS) and overall survival (OS). Germline and tumor BRCA1/2 genotyping was conducted using Illumina's next-generation sequencing (NGS). Results: PFS and OS were significantly shorter in PSROC patients with PV in BRCA1 compared to those with PV in BRCA2 (PFS:14.0 vs. 38.8 months, p = 0.007, OS: 21.8 vs. 62.0 months, p = 0.011). Notably, there was a significant difference in PFS based on the intragenic location of BRCA1 PV, with shorter PFS in patients with 1st/2nd relapse, harboring PV in BRCA1 RING domain compared to those with PV in the DNA binding domain (DBD) and BRCT domains (12.4 vs. 23.0 months, p = 0.046). No differences in PFS and OS were observed between patients with germline versus somatic BRCA1/2 PV (PFS:14.9 vs.19.3, p = 0.316, OS: not reached vs. 25.8 months; p = 0.224). However, there were significant differences in the reasons for OMT discontinuation between patients with germline and somatic BRCA1/2 PV, primarily due to adverse side effects. Conclusions: In summary, the type and location of BRCA1 and BRCA2 PV provide additional insight into the expected survival outcomes of olaparib MT in PSROC patients.Vir: Gynecologic oncology. - ISSN 0090-8258 (Vol. 190, Nov. 2024, str. 104-112)Vrsta gradiva - članek, sestavni del ; neleposlovje za odrasleLeto - 2024Jezik - angleškiCOBISS.SI-ID - 205458179
Avtor
Škof, Erik |
Stegel, Vida |
Šetrajčič Dragoš, Vita |
Blatnik, Ana, 9.8.1980- |
Gregorič, Brigita |
Škerl, Petra, doktorica biologije |
Klančar, Gašper, 1988- |
Zagožen Klasinc, Anja |
Bombač, Alenka |
Krajc, Mateja |
Novaković, Srdjan
Teme
rak jajčnikov |
mutacije BRCA |
dedni genotipi |
ovarian cancer |
BRCA mutations |
germline genotyping
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
| Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
|---|---|---|---|---|---|---|---|---|
| JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP | |
Faktor vpliva
Baze podatkov, v katerih je revija indeksirana
| Ime baze podatkov | Področje | Leto |
|---|
| Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
|---|---|
| Škof, Erik | 24572 |
| Stegel, Vida | 23343 |
| Šetrajčič Dragoš, Vita | 51870 |
| Blatnik, Ana, 9.8.1980- | 32428 |
| Gregorič, Brigita | 35833 |
| Škerl, Petra, doktorica biologije | 28388 |
| Klančar, Gašper, 1988- | 34575 |
| Zagožen Klasinc, Anja | ![]() |
| Bombač, Alenka | ![]() |
| Krajc, Mateja | 27594 |
| Novaković, Srdjan | 08007 |
Izberite prevzemno mesto:
Prevzem gradiva po pošti
Obvestilo
Gesla v Splošnem geslovniku COBISS
Izbira mesta prevzema
| Mesto prevzema | Status gradiva | Rezervacija |
|---|
Prosimo, počakajte trenutek.
